Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary SharesGlobeNewsWire • 1h
Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary SharesGlobeNewsWire • Tuesday
Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of DeathGlobeNewsWire • 11/04/24
Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/25/24
Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/10/24
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24GlobeNewsWire • 09/18/24
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 08/30/24
Purple Biotech Reports Second Quarter 2024 Financial Results and Business HighlightsGlobeNewsWire • 08/16/24
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price RuleGlobeNewsWire • 07/25/24
Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024GlobeNewsWire • 07/10/24
Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross ProceedsGlobeNewsWire • 07/02/24
Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival BenefitGlobeNewsWire • 06/27/24
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerGlobeNewsWire • 06/01/24
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingGlobeNewsWire • 04/25/24
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyGlobeNewsWire • 03/14/24
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom FisherZacks Investment Research • 03/13/24
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024GlobeNewsWire • 02/27/24